Fas and Fas ligand in human hepatocellular carcinoma

被引:12
作者
Takehara, T [1 ]
Hayashi, N [1 ]
机构
[1] Osaka Univ, Dept Mol Therapeut, Grad Sch Med, Suita, Osaka 5650871, Japan
关键词
D O I
10.1007/s005350170040
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
引用
收藏
页码:727 / 728
页数:2
相关论文
共 18 条
[1]
Expression of Fas/Fas ligand (FasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC) [J].
Fukuzawa, Y ;
Takahashi, K ;
Furuta, K ;
Tagaya, T ;
Ishikawa, T ;
Wada, K ;
Omoto, Y ;
Koji, T ;
Kakumu, S .
JOURNAL OF GASTROENTEROLOGY, 2001, 36 (10) :681-688
[2]
Higaki K, 1996, AM J PATHOL, V149, P429
[3]
Ito Y, 2000, BRIT J CANCER, V82, P1211
[4]
Kubo K, 1998, LIVER, V18, P117
[5]
Expression of Fas and Fas-related molecules in human hepatocellular carcinoma [J].
Lee, SH ;
Shin, MS ;
Lee, HS ;
Bae, JH ;
Lee, HK ;
Kim, HS ;
Kim, SY ;
Jang, JJ ;
Joo, M ;
Kang, YK ;
Park, WS ;
Park, JY ;
Oh, RR ;
Han, SY ;
Lee, JH ;
Kim, SH ;
Lee, JY ;
Yoo, NJ .
HUMAN PATHOLOGY, 2001, 32 (03) :250-256
[6]
Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53 [J].
Muller, M ;
Strand, S ;
Hug, H ;
Heinemann, EM ;
Walczak, H ;
Hofmann, WJ ;
Stremmel, W ;
Krammer, PH ;
Galle, PR .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (03) :403-413
[7]
The alteration of Fas receptor and ligand system in hepatocellular carcinomas:: How do hepatoma cells escape from the host immune surveillance in vivo? [J].
Nagao, M ;
Nakajima, Y ;
Hisanaga, M ;
Kayagaki, N ;
Kanehiro, H ;
Aomatsu, Y ;
Ko, S ;
Yagita, H ;
Yamada, T ;
Okumura, K ;
Nakano, H .
HEPATOLOGY, 1999, 30 (02) :413-421
[8]
Apoptosis by death factor [J].
Nagata, S .
CELL, 1997, 88 (03) :355-365
[9]
NATOLI G, 1995, ONCOGENE, V11, P1157
[10]
Immune privilege or inflammation? Insights into the Fas ligand enigma [J].
O'Connell, J ;
Houston, A ;
Bennett, MW ;
O'Sullivan, G ;
Shanahan, F .
NATURE MEDICINE, 2001, 7 (03) :271-274